Trial Profile
A retrospective study to evaluate the real-life experience of treating metastatic breast cancer patients with eribulin mesylate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record